Knowles (KN) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
28 Apr, 2026Executive summary
Q1 2026 revenue reached $153.1 million, up 16% year-over-year, driven by strong demand, new product introductions, and design wins across MedTech & Specialty Audio and Precision Devices segments.
Non-GAAP diluted EPS increased 50% year-over-year to $0.27, reflecting higher volume, margin expansion, and lower interest expense.
Net earnings from continuing operations were $11.3 million, up from a loss of $0.4 million in Q1 2025.
Cash generated by operating activities was $1.3 million, seasonally low but expected to improve for the full year.
Strong secular growth in MedTech, Defense, Industrial, and Electrification markets, with a healthy backlog and new design wins positioning for continued growth.
Financial highlights
Gross profit for Q1 2026 was $67.1 million (43.8% margin), up from $53.3 million (40.3%) in Q1 2025; non-GAAP gross profit was $69.7 million (45.5% margin).
Adjusted EBITDA for Q1 2026 was $35.3 million (23.1% margin), up from $26.7 million (20.2%) in Q1 2025.
R&D expense was $11.7 million, up 20.6% year-over-year; SG&A was $39.4 million, up 5.9%.
Interest expense declined to $1.5 million from $2.7 million, due to debt repayments.
Adjusted free cash flow was negative $3.1 million, compared to positive $18.3 million in Q1 2025, due to higher capital expenditures and working capital needs.
Outlook and guidance
Q2 2026 revenue guidance is $152–$162 million, with non-GAAP diluted EPS expected at $0.28–$0.32 and GAAP EPS at $0.18–$0.22.
Net cash from operating activities for Q2 2026 projected at $20–$30 million.
Full year 2026 revenue growth expected above the high end of the 4%–6% organic target.
Capital expenditures for 2026 projected at 4%–5% of revenues, focused on capacity expansion.
2026 adjusted EBITDA expected to exceed the 10%–14% cumulative annual growth target.
Latest events from Knowles
- Q4 and full year results surpassed guidance, with strong growth and positive 2026 outlook.KN
Q4 202512 Apr 2026 - Annual meeting covers director elections, executive pay, and auditor ratification for 2026.KN
Proxy Filing11 Mar 2026 - 2026 proxy covers director elections, executive pay, auditor ratification, and robust governance.KN
Proxy Filing11 Mar 2026 - Portfolio shift to MedTech, defense, and industrial boosts margins and growth outlook.KN
2024 Southwest IDEAS Conference3 Feb 2026 - Targets 8–10% annual revenue growth and 10–14% EBITDA growth through organic and M&A strategies.KN
Investor Day 20253 Feb 2026 - Q2 revenue up 18.3% to $204.7M; $249.4M goodwill impairment drove $259M net loss.KN
Q2 20242 Feb 2026 - Q3 revenue up 32% year-over-year; strategic divestiture and margin gains position for growth.KN
Q3 202418 Jan 2026 - Q1 2025 revenue hit $132.2M, with strong cash flow and robust Precision Devices demand.KN
Q1 202526 Dec 2025 - 2024 revenue up 21% and non-GAAP EPS up 32%, with strong cash flow and major new orders.KN
Q4 202423 Dec 2025